Valuation: DNAPrint Genomics, Inc.

Market Cap 25.78L 22.12L 20.65L 18.95L 35.63L 25Cr 36.22L 2.44Cr 95.43L 12Cr 96.82L 94.71L 41Cr P/E 2005
-0.23x
P/E 2006 -0.27x
Enterprise Value 13.64L 11.7L 10.92L 10.02L 18.85L 13Cr 19.16L 1.29Cr 50.48L 6.54Cr 51.21L 50.1L 22Cr EV / Sales 2005
1.89x
EV / Sales 2006 1.06x
Free-Float
100%
Yield 2005 *
-
Yield 2006 -
1 month 0
Extreme 1.0E-6
0
Current year 0
Extreme 1.0E-6
0
1 year 0
Extreme 1.0E-6
0
3 years 0
Extreme 1.0E-6
0
5 years 0
Extreme 1.0E-6
0
10 years 0
Extreme 0
0
Manager TitleAgeSince
Director of Finance/CFO - 23/12/2009
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.29T
+0.79%+1.96%+2.06%+24.28% 5.05TCr
-0.62%+4.58%+487.47%+624.71% 4.6TCr
+2.09%+4.96%+20.59%+95.21% 4.28TCr
+3.85%+3.13%+29.60%+16.50% 4.1TCr
-0.72%-3.91%+17.87%+47.98% 3.2TCr
+3.04%+1.89%+31.62%+143.62% 1.7TCr
+4.33%+1.63% - - 1.71TCr
+2.41%+3.11%+5.03%+34.45% 1.43TCr
+3.87%+1.98%+82.99%+45.80% 1.38TCr
Average +1.90%+1.81%+84.65%+129.07% 2.75TCr
Weighted average by Cap. +1.64%+2.37%+104.68%+154.65%

Financials

2005 2006
Net sales 12.76L 10.94L 10.22L 9L 17.63L 12Cr 17.92L 1.21Cr 47.21L 6.11Cr 47.89L 46.85L 20Cr 24.33L 20.87L 19.49L 17.88L 33.62L 23Cr 34.18L 2.3Cr 90.05L 12Cr 91.35L 89.37L 39Cr
Net income -87.16L -74.76L -69.81L -64.05L -1.2Cr -83Cr -1.22Cr -8.24Cr -3.23Cr -42Cr -3.27Cr -3.2Cr -138.14Cr -1.23Cr -1.06Cr -98.91L -90.75L -1.71Cr -118.03Cr -1.73Cr -12Cr -4.57Cr -59Cr -4.64Cr -4.54Cr -195.72Cr
Net Debt -7L -6L -6L -5L -10.18L -7.04Cr -10.35L -69.63L -27.27L -3.53Cr -27.66L -27.06L -12Cr -12.15L -10.42L -10L -9L -16.78L -12Cr -17.06L -1.15Cr -44.95L -5.82Cr -45.6L -44.61L -19Cr
Logo DNAPrint Genomics, Inc.
DNAPrint genomics, Inc. is a development-stage pharmaceutical company. As of March 15, 2007, the Company’s pharmacogenomics products were still in development. The Company generates revenues in its consumer, forensic and genotyping services, but these services have not resulted in the generation of significant revenues. During the year ended December 31, 2006, the Company’s revenues were from the sales of its ancestry product, AncestryByDNA and genotyping services. The Company provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers. Contract genotyping is the process of reading a genetic sequence and identifying differences in the sequence letters. This information helps researchers understand how human differences are expressed at the gene level.
Employees
25
  1. Stock Market
  2. Stocks
  3. DNAG Stock